Takeda Expands Antibody Collaboration With Xoma
This article was originally published in PharmAsia News
Executive Summary
Takeda and Xoma expanded their discovery and development agreement, increasing the number of therapeutic antibody programs and raising Xoma's potential earnings to $230 million, not including royalties, the companies announced Feb. 28
You may also be interested in...
DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial
TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12
DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial
TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12
Schering-Plough Expands Antibody Collaboration With Xoma
Deal builds on May agreement to discover and develop therapeutic monoclonal antibodies.